We are investigating MEI Pharma, Inc. (MEIP) (“MEI Pharma” or the “Company”) for potential violations of the federal securities laws. On July 2, 2020, MEI Pharma announced that it was discontinuing its Phase 3 study of Pracinostat, an oral histone deacetylase inhibitor being investigated in combination with azacitidine for the treatment of adults with newly diagnosed acute myeloid leukemia who are unfit for standard intensive chemotherapy. Specifically, the Company advised that an interim futility analysis of the ongoing Phase 3 study, undertaken by the study’s Independent Data Monitoring Committee, “has demonstrated it was unlikely to meet the primary endpoint of overall survival compared to the control group,” and that “[b]ased on the outcome of the interim analysis, the decision was made to discontinue the recruitment of patients and end the study,” which “was based on a lack of efficacy and not on safety concerns.” Following MEI Pharma’s announcement, the Company’s stock price fell $0.78 per share, or 18.27%, to close at $3.49 per share on July 2, 2020.